Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 16/20 | 0.58 |
| ▸ | BCHE | P06276 | 11/20 | 0.58 |
| ▸ | FAAH | O00519 | 1/20 | 0.58 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10109445 | 0.87 | ACHE (0.57) | ACHEBCHEFAAHMARK4HTR1A | |
| SCHEMBL8191829 | 0.80 | ACHE (0.58) | ACHEBCHEFAAHMARK4 | |
| SCHEMBL13522102 | 0.79 | ACHE (0.47) | ACHEBCHEFAAHMARK4HTR1A | |
| SCHEMBL13522101 | 0.78 | ACHE (0.67) | ACHEBCHEFAAHMARK4 | |
| SCHEMBL12043571 | 0.77 | ACHE (0.81) | ACHEBCHEFAAHMARK4 | |
| Rivastigmine SCHEMBL6382107 | 0.75 | ACHE (1.00) | ACHEBCHEFAAHMARK4 | |
| Rivastigmine SCHEMBL29614698 | 0.75 | ACHE (1.00) | ACHEBCHEFAAHMARK4 | |
| Rivastigmine SCHEMBL13841811 | 0.75 | ACHE (1.00) | ACHEBCHEFAAHMARK4 | |
| Rivastigmine SCHEMBL1170429 | 0.75 | ACHE (1.00) | ACHEBCHEFAAHMARK4 | |
| Rivastigmine SCHEMBL6382629 | 0.75 | ACHE (1.00) | ACHEBCHEFAAHMARK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101782-B2 | Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory | COLUCID PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101782-B2 | Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory | COLUCID PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | COLUCID PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | COLUCID PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261950-A1 | Compounds that inhibit cholinesterase | ACHE, BCHE, CHAT | ACHE 1/4885BCHE 2/4885FAAH 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.